Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib rollover study in advanced solid tumors
NCT03309150Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in solid tumor (advanced stage), sponsored by Merck KGaA. Primary endpoint: Adverse Events up to 6 years. Started Jan 2018; status: completed.
02
Drugs
berzosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03309150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03309150.